PE20212157A1 - Composiciones farmaceuticas que comprenden meloxicam - Google Patents

Composiciones farmaceuticas que comprenden meloxicam

Info

Publication number
PE20212157A1
PE20212157A1 PE2021001288A PE2021001288A PE20212157A1 PE 20212157 A1 PE20212157 A1 PE 20212157A1 PE 2021001288 A PE2021001288 A PE 2021001288A PE 2021001288 A PE2021001288 A PE 2021001288A PE 20212157 A1 PE20212157 A1 PE 20212157A1
Authority
PE
Peru
Prior art keywords
meloxicam
migraine
rizatriptan
pain
administered
Prior art date
Application number
PE2021001288A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PE20212157A1 publication Critical patent/PE20212157A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

SSe describe en la presente, composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinacion con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocineticas del NSAID para el tratamiento de dolor como migrana, artritis, y otras afecciones. Tambien se describen metodos para tratar el dolor, como migrana, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migrana. Para la migrana, estos metodos pueden ser particularmente utiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano esta sufriendo de un ataque agudo de dolor de migrana o aura de migrana. En algunas modalidades, la combinacion de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.
PE2021001288A 2019-02-06 2020-02-06 Composiciones farmaceuticas que comprenden meloxicam PE20212157A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31
PCT/US2020/017046 WO2020163620A1 (en) 2019-02-06 2020-02-06 Pharmaceutical compositions comprising meloxicam

Publications (1)

Publication Number Publication Date
PE20212157A1 true PE20212157A1 (es) 2021-11-09

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001288A PE20212157A1 (es) 2019-02-06 2020-02-06 Composiciones farmaceuticas que comprenden meloxicam

Country Status (17)

Country Link
EP (1) EP3920909A4 (es)
JP (3) JP7237386B2 (es)
KR (1) KR20210118880A (es)
CN (1) CN113423397A (es)
AU (2) AU2020218253B2 (es)
BR (1) BR112021015467A2 (es)
CA (2) CA3213549A1 (es)
CL (1) CL2021002070A1 (es)
CO (1) CO2021010380A2 (es)
CR (1) CR20210420A (es)
EC (1) ECSP21060962A (es)
IL (1) IL285389A (es)
MA (1) MA54904A (es)
MX (1) MX2021009435A (es)
PE (1) PE20212157A1 (es)
SG (1) SG11202107926XA (es)
WO (1) WO2020163620A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126841B1 (en) 1998-11-02 2004-12-15 Merck & Co., Inc. Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SG11201706123XA (en) * 2015-02-10 2017-08-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
SI3256138T1 (sl) 2015-11-25 2022-07-29 Axsome Therapeutics, Inc. Farmacevtski sestavki, ki obsegajo meloksikam
KR20190066607A (ko) * 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CA3121746A1 (en) 2017-01-04 2018-07-12 Herriot TABUTEAU Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN116999563A (zh) 2017-05-10 2023-11-07 艾克萨姆治疗公司 包含美洛昔康的药物组合物

Also Published As

Publication number Publication date
CR20210420A (es) 2021-12-22
JP7237386B2 (ja) 2023-03-13
MX2021009435A (es) 2021-09-10
JP2023062144A (ja) 2023-05-02
AU2020218253A1 (en) 2021-08-12
CN113423397A (zh) 2021-09-21
CA3128940C (en) 2023-11-07
CL2021002070A1 (es) 2022-04-01
AU2020218253B2 (en) 2023-02-23
WO2020163620A1 (en) 2020-08-13
CA3128940A1 (en) 2020-08-13
ECSP21060962A (es) 2021-11-30
BR112021015467A2 (pt) 2021-10-05
JP2024026732A (ja) 2024-02-28
KR20210118880A (ko) 2021-10-01
JP7420990B2 (ja) 2024-01-23
JP2022519670A (ja) 2022-03-24
AU2023202545A1 (en) 2023-05-18
SG11202107926XA (en) 2021-08-30
MA54904A (fr) 2021-12-15
CO2021010380A2 (es) 2021-09-30
IL285389A (en) 2021-09-30
CA3213549A1 (en) 2020-08-13
EP3920909A4 (en) 2022-11-30
EP3920909A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
MX2024005716A (es) Composiciones farmaceuticas que comprenden meloxicam.
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
ECSP19014247A (es) Formas de dosificación para tratar y prevenir trastornos del sueño
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
CO2020015377A2 (es) Moduladores de la expresión de apol1
ECSP21060962A (es) Composiciones farmacéuticas que comprenden meloxicam
MA39443A1 (fr) Nouvelle formulation de méloxicam
MX2020010417A (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.
MX2021003651A (es) Formulacion que comprende aceite ozonizado en el tratamiento de un tumor.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
PE20091030A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa